sur Tacalyx GmbH
Tacalyx Appoints Jean Engela as CEO to Drive Growth
Tacalyx GmbH, a biotech company based in Berlin, has appointed Jean Engela as its new Chief Executive Officer. Engela brings over two decades of experience in drug research and development. Previously, he was CEO at NBE Therapeutics and an Executive Drug Development Leader at Boehringer Ingelheim. His role will focus on guiding Tacalyx as it transitions into a clinical-stage company.
With the appointment, Tacalyx's former CEO, Dr. Peter Sondermann, will now serve as Chief Scientific Officer. Chairman Klaus Schollmeier expressed gratitude for Sondermann’s contributions while highlighting Engela's leadership strengths.
Under Engela, Tacalyx plans to enhance its targeted therapeutic developments for cancer treatment, including the promising TCX-201 compound poised for IND-enabling studies.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Tacalyx GmbH